Table 1.
SCCS cohort to study COVID-19 vaccination exposure on blood clots. Characteristics of patients who experienced at least one blood clot event and had at least one dose of mRNA-based vaccination from Dec 1st, 2020, to August 31st, 2022.
| Patient Characteristics in SCCS Study | |||
|---|---|---|---|
| Dose 1 (N = 18,466) |
Dose 2 (N = 17,523) |
||
| AGE | |||
| 18–30 | 161 (0.87%) | 142 (0.81%) | |
| 31–50 | 1,416 (7.67%) | 1,304 (7.44%) | |
| 51–65 | 4,422 (23.95%) | 4,166 (23.77%) | |
| > 65 | 12,467 (67.51%) | 11,911 (68.97%) | |
| GENDER | |||
| Female | 8,691 (47.06%) | 8,247 (47.06%) | |
| Male | 9,775 (52.94%) | 9,276 (52.94%) | |
| RACE | |||
| White Race | 14,803 (80.16%) | 14,089 (80.40%) | |
| Black Race | 2,697 (14.61%) | 2,514 (14.35%) | |
| Other | 966 (5.23%) | 920 (5.25%) | |
| CHARLSON COMORBIDITY INDEX (CCI) | |||
| 0 | 2,938 (15.91%) | 2,801 (15.98%) | |
| 1–2 | 5,153 (27.91%) | 4,910 (28.02%) | |
| 3–4 | 5,326 (28.84%) | 5,061 (28.88%) | |
| >=5 | 5,049 (27.34%) | 4,751 (27.11%) | |
| NUM. BLOOD CLOTS IN RISK PERIODS | |||
| 763 | 894 | ||